Stoney Hill Capital

What Stoney Hill Capital does

Stoney Hill Capital is a privately held, boutique venture capital firm founded in 2021 and headquartered in the Lehigh Valley, United States. The firm invests in early to mid-stage pharmaceutical service and technology providers, with a vertical mandate spanning clinical development, regulatory services, data and technology platforms, and commercialization solutions. It is founder-led: Joseph Kohles, Ph.D. serves as Founding Partner, bringing over 20 years of pharmaceutical services experience including executive roles at Roche and Pfizer and prior leadership as Chief Medical Officer at Envision Pharma Group and Founding Partner / Managing Director at Alligent Group.

The firm packages its offering as three service pillars: Invest (capital to fuel growth of next-generation pharma service companies), Advise (strategic guidance from industry veterans), and Network (access to pharmaceutical leaders, partners, and decision-makers). Stoney Hill Capital does not operate a technology product platform; the underlying "product" is capital allocation plus value-add advisory and network access for portfolio companies across the pharmaceutical ecosystem.

The revenue model is investment returns: as a private investment firm, Stoney Hill Capital generates economics through equity appreciation, exit events, dividends, and (implicitly) management fees and carried interest on its fund vehicle, though no AUM, fund size, fee structure, or portfolio company count is publicly disclosed. Go-to-market is relationship-driven via direct engagement, industry network referrals, and a "Schedule a Chat" call-to-action on the firm website (stoneyhillcap.com). Distribution scope is tagged as global, despite a single disclosed U.S. office location. Headcount is 1-10 employees.

Name

Stoney Hill Capital

Legal name

Stoney Hill Capital

Website

https://stoneyhillcap.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Stoney Hill Capital is a privately held, boutique venture capital firm founded in 2021 that invests in early to mid-stage pharmaceutical service and technology providers, offering capital, strategic guidance, and industry network access to portfolio companies across clinical development through commercialization.

Ownership category

akta.pro rank

Product category

Venture Capital / Pharmaceutical Investment Services

NAICS

Other Financial Investment Activities (5239)

SIC

Investment Advice (6282)

akta.pro primary industry

Roll-Up / Buy-and-Build ETA (FSANALAF)

Keywords

• Venture capital
• Pharmaceutical services
• Healthcare investing
• Early-stage growth capital
• Pharma advisory services

Headquarters

HQ city

Lehigh Valley

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Revenue model

1. Investment Returns: As a capital investment firm, Stoney Hill Capital generates returns through equity investments in early to mid-stage pharmaceutical service and technology companies. The firm provides capital to fuel growth and likely generates revenue through exit events, dividends, or equity appreciation from portfolio companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Stoney Hill Capital is a venture capital firm that invests in early to mid-stage pharmaceutical service and technology providers. The firm provides growth capital, strategic guidance from industry veterans, and access to a network of pharmaceutical leaders and decision-makers to help portfolio companies scale across clinical development, regulatory services, data and technology platforms, and commercialization solutions.

Product overview

Stoney Hill Capital is an investment and advisory firm that provides capital, strategic guidance, and network access to early to mid-stage pharmaceutical service and technology companies. The firm does not offer a product-based platform; rather, it delivers three core service offerings: Invest (capital to fuel growth of next-generation pharma service companies), Advise (strategic guidance from industry veterans), and Network (access to pharmaceutical leaders, partners, and decision-makers). These services support companies across clinical development, regulatory services, data and technology platforms, and commercialization solutions.

Differentiator

Problem solved

Functional benefit

Products and services

• Invest
• Advise
• Network

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves3 records

Expansion highlights3 records

Others

• Silicon Valley Bank (Healthcare Practice): Banking and capital provider targeting healthcare and life sciences companies, including venture lending and equity financing. Adjacent ecosystem participant serving similar pharma services and technology clients.

Direct peers

• Longitude Capital: Healthcare-dedicated venture and growth investment firm with deep sector expertise, investing in pharmaceutical and medical technology companies. Comparable in being a sector-specialist investor focused on healthcare innovation.
• NovaQuest Capital Management: Investment firm specializing in healthcare and pharmaceutical services, with expertise in financing commercial-stage and late-development assets. Comparable in pharma services focus and bespoke financing structures.
• Health Catalyst Capital: A venture capital firm investing in healthcare and pharmaceutical services and technology companies. Closely comparable to Stoney Hill Capital in stage focus, vertical specialization, and support-oriented value-add beyond capital.
• Atlas Venture: Early-stage venture capital firm focused on biotech and pharmaceutical innovation. Comparable in stage focus and operating-partner model, though typically more biotech-discovery oriented than services.

Broad incumbents

• OrbiMed: One of the largest healthcare-dedicated investment firms globally, investing across pharma, biotech, medical devices, and healthcare services. Operates at far greater scale than Stoney Hill but competes in overlapping sub-sectors.
• RA Capital Management: Healthcare-focused investment firm with dedicated venture capital and public equity strategies. Comparable as a sector-specialist investor with deep scientific and clinical expertise supporting portfolio companies.
• Frazier Healthcare Partners: Established healthcare-focused venture and growth firm with a longer track record and broader portfolio across pharma services, biopharma, and medical devices. Comparable in vertical focus but operates at significantly larger scale.
• Deerfield Management: Healthcare-focused investment manager with multiple strategies across public and private healthcare. Overlaps with Stoney Hill in life sciences and pharma services investing, though at a much larger AUM scale.

Emerging players

• Health Enterprise Partners: Growth equity firm investing in healthcare services and technology companies. Comparable in targeting the healthcare services layer, with similar focus on strategic guidance alongside capital.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/stoney-hill-capital

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stoney Hill Capital